JPMorgan Chase & Co. cut shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a neutral rating to an underweight rating in a report released on Tuesday, MarketBeat reports. The firm currently has $18.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $20.00.
A number of other analysts also recently weighed in on AMAG. Cantor Fitzgerald set a $18.00 price objective on AMAG Pharmaceuticals and gave the company a hold rating in a report on Friday, November 2nd. BidaskClub downgraded AMAG Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday. Cowen set a $19.00 price objective on AMAG Pharmaceuticals and gave the company a hold rating in a report on Thursday, November 1st. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $21.97.
NASDAQ AMAG traded down $0.35 on Tuesday, reaching $17.84. The company had a trading volume of 693,138 shares, compared to its average volume of 966,978. The company has a market capitalization of $644.43 million, a price-to-earnings ratio of -3.12 and a beta of 0.23. AMAG Pharmaceuticals has a fifty-two week low of $11.95 and a fifty-two week high of $26.10. The company has a quick ratio of 2.72, a current ratio of 2.86 and a debt-to-equity ratio of 0.34.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). The company had revenue of $122.20 million during the quarter, compared to analyst estimates of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($4.31) earnings per share. Research analysts expect that AMAG Pharmaceuticals will post -2.85 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of AMAG. Advisors Asset Management Inc. boosted its position in AMAG Pharmaceuticals by 791.6% during the second quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 52,356 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in AMAG Pharmaceuticals during the second quarter valued at $156,000. Meeder Asset Management Inc. boosted its position in AMAG Pharmaceuticals by 590.9% during the second quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock valued at $174,000 after acquiring an additional 7,652 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in AMAG Pharmaceuticals during the third quarter valued at $188,000. Finally, NumerixS Investment Technologies Inc boosted its position in AMAG Pharmaceuticals by 243.2% during the second quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 9,000 shares during the last quarter.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.